- Home
- YUMC vs RVMD Comparison
YUMC vs RVMD Comparison
Compare YUMC & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YUMC | RVMD |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7B | 15.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | YUMC | RVMD |
|---|---|---|
| Price | $49.41 | $96.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $100.13 |
| AVG Volume (30 Days) | 1.1M | ★ 5.6M |
| Earning Date | 02-04-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 6.57 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $11,569,000,000.00 | N/A |
| Revenue This Year | $5.49 | N/A |
| Revenue Next Year | $5.76 | $740.40 |
| P/E Ratio | $21.09 | ★ N/A |
| Revenue Growth | ★ 3.29 | N/A |
| 52 Week Low | $41.00 | $29.17 |
| 52 Week High | $53.99 | $124.49 |
Technical Indicators
Market Signals| Indicator | YUMC | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 55.56 | 46.96 |
| Support Level | $48.53 | $96.72 |
| Resistance Level | $51.38 | $101.93 |
| Average True Range (ATR) | 1.03 | 4.16 |
| MACD | 0.17 | -3.41 |
| Stochastic Oscillator | 56.25 | 15.13 |
Price Performance
Historical ComparisonAbout YUMC Yum China Holdings Inc.
With more than 18,000 units and USD 12 billion in systemwide sales in 2025, Yum China is the largest restaurant operator in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC and Pizza Hut, but the company's portfolio also includes other brands such as Little Sheep, Taco Bell, Huang Ji Huang, and Lavazza. Yum China is a trademark licensee of Yum Brands, paying 3% of KFC and Pizza Hut's systemwide sales to the company it separated from 2016.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.